Click image to enlarge
The obvious sharp marginal trend reversal of Venlafaxine Total Prescriptions in 2004 to 2006 correlates with: -
1 The “Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)” published December 2004; which single out Venlafaxine for its potential for cardiotoxicity and toxicity in overdose.
2 “NICE Clinical Guidelines 23: Depression” published December 2004, issued new guidelines for treatment with Venlafaxine; 184.108.40.206 restricting treatment initiation to specialist mental health medical practitioners and in 220.127.116.11 reinforcing that venlafaxine treatment should only be managed under supervision of specialist mental health medical practitioners.
Both 18.104.22.168 and 22.214.171.124 recommendations were surreptitiously deleted from the revised prescribing advice issued 31 May 2006 at which point increasing venlafaxine prescription trends resumed.
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007: